Mable
trymable.comGenomics-based telehealth for personalised migraine care
Health & Wellnesstelehealthgenomicsmigraineprecision-medicineneurologydna-testingpersonalized-care
About
Mable, operated by Neurolytic Healthcare Inc., is a telehealth platform that combines genomic and biomarker data with telemedicine to deliver personalized migraine treatment plans. Patients complete online consultations and DNA testing, and receive precision medicine recommendations tailored to their genetic profile. The platform provides ongoing virtual support to adjust treatments over time based on patient progress.
Problem
Traditional migraine treatment relies on trial-and-error medication prescribing, leading to delayed and often suboptimal outcomes for patients.
For
Migraine sufferers seeking personalized, genomics-informed treatment
How it works
Patients complete an online consultation and DNA test, and Mable analyzes their genetic and biomarker data to generate a personalized migraine treatment plan delivered via telehealth.
Business model
unknown
Status
unknown
Company
Neurolytic Healthcare, Inc.
Launched
2019
Founders
- Inna Nicole Thalmann
- Roman Rothaermel
- Chris Eijsbouts
- Kumeren Govnder